Experiences with recombinant factor VIIa in haemophiliacs.
Hedner
U
U
Biopharmaceuticals Division Research, Novo Nordisk, Bagsvaerd, Denmark.
D000818:Animals; D001323:Autoantibodies / Q000276:immunology; D002460:Cell Line; D006224:Cricetinae; D004341:Drug Evaluation; D005168:Factor VII Deficiency / Q000150:complications / Q000188:drug therapy*; D005169:Factor VIII / Q000276:immunology; D015942:Factor VIIa / Q000276:immunology / Q000627:therapeutic use*; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy*; D006470:Hemorrhage / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007430:Intraoperative Care; D007668:Kidney; D008297:Male; D008647:Mesocricetus; D010314:Partial Thromboplastin Time; D011994:Recombinant Proteins / Q000627:therapeutic use
D001323:Autoantibodies; D011994:Recombinant Proteins; D005169:Factor VIII; D015942:Factor VIIa